In alignment with prior outcomes and of considerable clinical interest, a high EZH2-score-II was associated with a higher tumor-grading: G1 M = 3.46; SD = 1.65; 95% CI 2.79–4.13; G2 M = 5.03; SD = 2.25; 95% CI 4.50–5.55; G3 M = 5.09; SD = 1.90; 95% CI 4.26–5.91 (Kruskal-Wallis-test, p = 0.002; Likelihood ratio, p = 0.013; crosstab analysis linear-by-linear association, p = 0.007). Here, EZH2 is linked to neoplasm.